Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3366-3375

  Bonehill, Aude ^a   Van Nuffel, An M T ^a   Corthals, Jurgen ^a   Tuyaerts, Sandra ^a   Heirman, Carlo ^a   François, Violaine ^b   Colau, Didier ^b   Van Der Bruggen, Pierre ^b   Neyns, Bart ^c   Thielemans, Kris ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UZ Brussel ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD70 ANTIGEN; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; MELAN A; MELAN A A2 PEPTIDE; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PEPTIDE DERIVATIVE; TOLL LIKE RECEPTOR 4; TRIMIX; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DENDRITIC CELL; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; MALE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD137; ANTIGENS, CD70; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; VACCINATION;

EID: 66149186858     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2982     Document Type: Article

References (31)

1. Lens M. Current clinical overview of cutaneous melanoma. Br J Nurs 2008;17:300-305
2. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008;8:315-323
3. Lesterhuis WJ, Aarntzen EH, De Vries IJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008;66:118-134
4. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007;56:1513-1537 (Pubitemid 47094397)
5. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6:476-483
6. Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008;16:1170-1180
7. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000;96:91-99 (Pubitemid 30456456)
8. Cisco RM, Abdel-Wahab Z, Dannull J, et al. Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 2004;172:7162-7168 (Pubitemid 38669160)
9. Lapointe R, Toso JF, Butts C, Young HA, Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol 2000;30:3291-3298
10. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17:275-281 (Pubitemid 40692662)
11. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311-316
12. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-6282 (Pubitemid 37467251)
13. Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VF, Berneman ZN. Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 2005;43:213-216 (Pubitemid 41582141)
14. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004;172:6649-6657 (Pubitemid 38669100)
15. Kreiter S, Selmi A, Diken M, et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 2008;180:309-318
16. + cytolytic T lymphocytes. Cancer Res 2000;60:6272-6275
17. Bonehill A, Heirman C, Tuyaerts S, et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003;63:5587-5594 (Pubitemid 37139882)
18. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
19. + T-cells responding to antigen without requiring knowledge of epitope-specificities. Blood 2007.
20. + T cells differently expressing three cytolytic effector molecules. J Immunol 2006;177:4330-4340
21. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258
22. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-2261
23. Bontkes HJ, Kramer D, Ruizendaal JJ, et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007;14:366-375 (Pubitemid 46231930)
24. Liao X, Li Y, Bonini C, et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004;9:757-764 (Pubitemid 38660429)
25. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-70 interactions. Nat Immunol 2003;4:49-54. (Pubitemid 36104708)
26. Moreno M, Molling JW, von Mensdorff-Pouilly S, et al. IFN-γ-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 2008;181:2446-2454
27. Molling JW, Moreno M, van der Vliet HJ, et al. Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 2008;129:182-194
28. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
29. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 2000;97:2185-2190 (Pubitemid 30134043)
30. Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol 2004;172:2232-2237 (Pubitemid 38182371)
31. Dubsky P, Saito H, Leogier M, et al. Eur J Immunol 2007;37:1678-1690